.

Pharmaceutical Business Intelligence

  • Predict branded drug patent expiration
  • Uncover prior art in abandoned patent applications and expired patents
  • Set up watchlists for daily email updates

► Plans and Pricing

DrugPatentWatch Database Preview

MOZOBIL Drug Profile

« Back to Dashboard

Which patents cover Mozobil, and what substitute generic drugs are available?

Mozobil is a drug marketed by Genzyme and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-seven patent family members in twenty-nine countries.

The generic ingredient in MOZOBIL is plerixafor. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the plerixafor profile page.

Summary for Tradename: MOZOBIL

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list64
Clinical Trials: see list64
Drug Prices:see details
DailyMed Link:MOZOBIL at DailyMed

Pharmacology for Tradename: MOZOBIL

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 2008RXYesYes6,987,102► Subscribe ► Subscribe
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 2008RXYesYes7,897,590► Subscribe ► Subscribe
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 2008RXYesYesRE42152► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MOZOBIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 20085,583,131► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: MOZOBIL

Drugname Dosage Strength RLD Submissiondate
plerixaforInjection24 mg/1.2 mL vials (20 mg/mL)Mozobil12/17/2012

Non-Orange Book Patents for Tradename: MOZOBIL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,169,750Methods to mobilize progenitor/stem cells► Subscribe
7,935,692Methods to mobilize progenitor/stem cells► Subscribe
5,583,131 Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MOZOBIL

Country Document Number Estimated Expiration
Austria273964► Subscribe
China102302493► Subscribe
South Africa200400658► Subscribe
Hungary9401786► Subscribe
Luxembourg92033► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: MOZOBIL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0120014 00064Estonia► SubscribePRODUCT NAME: MOZOBIL - PLERIXAFOR;REG NO/DATE: C(2009)6238 31.07.2009
90023-9Sweden► SubscribePRODUCT NAME: PLERIXAFOR, VALFRITT I FORMEN AV ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/09/534/001 20090804
C/GB12/031United Kingdom► SubscribePRODUCT NAME: PLERIXAFOR OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; REGISTERED: UK EU/1/09/537/001 20090804
033Luxembourg► Subscribe92033, EXPIRES: 20240731
C/GB10/004United Kingdom► SubscribePRODUCT NAME: PLERIXAFOR IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTERED: UK EU/1/09/537/001 20090731; REASON FOR LAPSE: SURRENDERED
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc